Pugatch: Pandemic Has Shown IPR-Based System Is Working
Executive Summary
Pugatch Consilium managing director, Meir Perez Pugatch, says that IP has been the “bridge” in the various biopharma R&D collaborations that have helped deliver unprecedented results during the pandemic. He also weighs in on the divisive proposal of waiver of intellectual property rights for vaccines, treatments and diagnostics relating to COVID-19.
You may also be interested in...
Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP
AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.
WTO Chief: Pharma Needs To 'Lift The Veil Of Opaqueness' In COVID-19 Vaccine Contracts
WTO director general says pharma could have done more on voluntary licensing for COVID-19 vaccines and also calls for better transparency of pricing and contracts to ensure “a level playing field” when it comes to saving lives.
Natco And MSN Battle Chugai Over Alectinib In India
Roche affiliate Chugai has moved court in India seeking to restrain Natco and MSN Laboratories over alleged infringement of its patent concerning Alecensa. The Indian firms, however, contend their actions fall under the ambit of the country’s “Bolar exemption” provision.